Advertisement

Impact of Nuclear Receptors CAR, PXR, FXR, and VDR, and Their Ligands On Enzymes and Transporters

  • Rommel G. Tirona
Chapter

Abstract

Nuclear receptors play a central role on the mechanism of induction-type drug–drug interactions by acting as xenosensing transcription factors. Together, PXR, CAR, FXR, and VDR form a core group of nuclear receptors that regulate the expression of a number of important drug-metabolizing enzymes and drug transporters. In this chapter, the molecular determinants of adaptive response to drug exposure are detailed in the context of clinical relevance and drug development.

Keywords

Nuclear Receptor Constitutive Androstane Receptor Primary Human Hepatocyte Cerebrotendinous Xanthomatosis Human Immunodeficiency Virus Protease Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Acocella G (1978) Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 3:108–127.PubMedCrossRefGoogle Scholar
  2. Adesnik M, Bar-Nun S, Maschio F, Zunich M, Lippman A and Bard E (1981) Mechanism of induction of cytochrome P-450 by phenobarbital. J Biol Chem 256:10340–10345.PubMedGoogle Scholar
  3. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ and Suchy FJ (2001) Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 276:28857–28865.PubMedCrossRefGoogle Scholar
  4. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F, Guguen-Guillouzo C and Guillouzo A (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75–83.PubMedCrossRefGoogle Scholar
  5. Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, Moore DD, Borst P and Schuetz JD (2004) Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 279:22250–22257.PubMedCrossRefGoogle Scholar
  6. Baciewicz AM, Chrisman CR, Finch CK and Self TH (2008) Update on rifampin and rifabutin drug interactions. Am J Med Sci 335:126–136.PubMedCrossRefGoogle Scholar
  7. Baes M, Gulick T, Choi HS, Martinoli MG, Simha D and Moore DD (1994) A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol Cell Biol 14:1544–1551.PubMedGoogle Scholar
  8. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J and O‘Malley BW (1988) Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A 85:3294–3298.PubMedCrossRefGoogle Scholar
  9. Barbier O, Torra IP, Sirvent A, Claudel T, Blanquart C, Duran-Sandoval D, Kuipers F, Kosykh V, Fruchart JC and Staels B (2003) FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 124:1926–1940.PubMedCrossRefGoogle Scholar
  10. Bauer B, Hartz AM, Fricker G and Miller DS (2004) Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 66:413–419.PubMedGoogle Scholar
  11. Bauer B, Hartz AM, Lucking JR, Yang X, Pollack GM and Miller DS (2008) Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier. J Cereb Blood Flow Metab 28:1222–1234.PubMedCrossRefGoogle Scholar
  12. Bauer B, Yang X, Hartz AM, Olson ER, Zhao R, Kalvass JC, Pollack GM and Miller DS (2006) In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 70:1212–1219.PubMedCrossRefGoogle Scholar
  13. Beischlag TV, Luis Morales J, Hollingshead BD and Perdew GH (2008) The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 18:207–250.PubMedGoogle Scholar
  14. Benedetti MS (2000) Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 14:301–319.PubMedCrossRefGoogle Scholar
  15. Bertilsson G, Berkenstam A and Blomquist P (2001) Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. Biochem Biophys Res Commun 280:139–144.PubMedCrossRefGoogle Scholar
  16. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P and Berkenstam A (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 95:12208–12213.PubMedCrossRefGoogle Scholar
  17. Bertilsson L, Hojer B, Tybring G, Osterloh J and Rane A (1980) Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther 27:83–88.PubMedCrossRefGoogle Scholar
  18. Blumberg B, Sabbagh W, Jr., Juguilon H, Bolado J, Jr., van Meter CM, Ong ES and Evans RM (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195–3205.PubMedCrossRefGoogle Scholar
  19. Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai SY, Moustafa T, Zollner G, Lee JY and Ballatori N (2006) Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol 290:G1124–G1130.Google Scholar
  20. Briz O, Romero MR, Martinez-Becerra P, Macias RI, Perez MJ, Jimenez F, San Martin FG and Marin JJ (2006) Oatp8/1B3-mediated cotransport of bile acids and glutathione. An export pathway for organic anions from hepatocytes?. J Biol Chem 281:30326–30335.PubMedCrossRefGoogle Scholar
  21. Burbach KM, Poland A and Bradfield CA (1992) Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc Natl Acad Sci USA 89:8185–8189.PubMedCrossRefGoogle Scholar
  22. Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF and Eichelbaum M (2005) Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 67:1954–1965.PubMedCrossRefGoogle Scholar
  23. Carter BA, Taylor OA, Prendergast DR, Zimmerman TL, Von Furstenberg R, Moore DD and Karpen SJ (2007) Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr Res 62:301–306.PubMedCrossRefGoogle Scholar
  24. Castro-Gago M, Novo-Rodriguez MI, Gomez-Lado C, Rodriguez-Garcia J, Rodriguez-Segade S and Eiris-Punal J (2007) Evolution of subclinical hypothyroidism in children treated with antiepileptic drugs. Pediatr Neurol 37:426–430.PubMedCrossRefGoogle Scholar
  25. Chawla A, Repa JJ, Evans RM and Mangelsdorf DJ (2001) Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866–1870.PubMedCrossRefGoogle Scholar
  26. Chen Y, Ferguson SS, Negishi M and Goldstein JA (2003) Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 64:316–324.PubMedCrossRefGoogle Scholar
  27. Chen Y, Ferguson SS, Negishi M and Goldstein JA (2004) Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308:495–501.PubMedCrossRefGoogle Scholar
  28. Conney AH, Davison C, Gastel R and Burns JJ (1960) Adaptive increases in drug-metabolizing enzymes induced by phenobarbital and other drugs. J Pharmacol Exp Ther 130:1–8.PubMedGoogle Scholar
  29. Conney AH, Jacobson M, Schneidman K and Kuntzman R (1965) Induction of liver microsomal cortisol 6beta-hydroxylase by diphenylhydantoin or phenobarbital: an explanation for the increased excretion of 6-hydroxycortisol in humans treated with these drugs. Life Sci 4:1091–1098.PubMedCrossRefGoogle Scholar
  30. Cucinell SA, Koster R, Conney AH and Burns JJ (1963) Stimulatory Effect Of Phenobarbital On The Metabolism Of Diphenylhydantoin. J Pharmacol Exp Ther 141:157–160.PubMedGoogle Scholar
  31. Curran PG and DeGroot LJ (1991) The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland. Endocr Rev 12:135–150.PubMedCrossRefGoogle Scholar
  32. de Haan W, de Vries-van der Weij J, Mol IM, Hoekstra M, Romijn JA, Jukema JW, Havekes LM, Princen HM and Rensen PC (2009) PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice. Biochim Biophys Acta 1791:191–197.PubMedGoogle Scholar
  33. Dekeyser JG, Stagliano MC, Auerbach SS, Prabu KS, Jones AD and Omiecinski CJ (2009) Di(2-ethylhexyl) phthalate is a highly potent agonist for the human constitutive androstane receptor splice variant, CAR2. Mol Pharmacol 75:1003–1013.CrossRefGoogle Scholar
  34. Denson LA, Sturm E, Echevarria W, Zimmerman TL, Makishima M, Mangelsdorf DJ and Karpen SJ (2001) The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 121:140–147.PubMedCrossRefGoogle Scholar
  35. DeVane CL (2003) Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull 37 Suppl 2:25–42.PubMedGoogle Scholar
  36. Ding X, Lichti K and Staudinger JL (2006) The mycoestrogen zearalenone induces CYP3A through activation of the pregnane X receptor. Toxicol Sci 91:448–455.PubMedCrossRefGoogle Scholar
  37. Ding X and Staudinger JL (2005a) Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase a signal transduction pathway. J Pharmacol Exp Ther 312:849–856.PubMedCrossRefGoogle Scholar
  38. Ding X and Staudinger JL (2005b) Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C. Biochem Pharmacol 69:867–873.PubMedCrossRefGoogle Scholar
  39. Dresser GK, Schwarz UI, Wilkinson GR and Kim RB (2003) Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects. Clin Pharmacol Ther 73:41–50.PubMedCrossRefGoogle Scholar
  40. Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, Smyth CM, Keeling PW, O‘Donoghue D, O‘Sullivan M, O‘Morain C, Mahmud N, Wikstrom AC, Kelleher D and McManus R (2006) The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130:341–348 quiz 592.PubMedCrossRefGoogle Scholar
  41. Drocourt L, Ourlin JC, Pascussi JM, Maurel P and Vilarem MJ (2002) Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 277:25125–25132.PubMedCrossRefGoogle Scholar
  42. Drocourt L, Pascussi JM, Assenat E, Fabre JM, Maurel P and Vilarem MJ (2001) Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab Dispos 29:1325–1331.PubMedGoogle Scholar
  43. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ and Fattinger K (2000) St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598–604.PubMedCrossRefGoogle Scholar
  44. Dussault I, Beard R, Lin M, Hollister K, Chen J, Xiao JH, Chandraratna R and Forman BM (2003a) Identification of gene-selective modulators of the bile acid receptor FXR. J Biol Chem 278:7027–7033.PubMedCrossRefGoogle Scholar
  45. Dussault I, Yoo HD, Lin M, Wang E, Fan M, Batta AK, Salen G, Erickson SK and Forman BM (2003b) Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. Proc Natl Acad Sci USA 100:833–838.PubMedCrossRefGoogle Scholar
  46. Echchgadda I, Song CS, Oh T, Ahmed M, De La Cruz IJ and Chatterjee B (2007) The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4 in the regulation of human steroid-/bile acid-sulfotransferase. Mol Endocrinol 21:2099–2111.PubMedCrossRefGoogle Scholar
  47. Echchgadda I, Song CS, Roy AK and Chatterjee B (2004) Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol Pharmacol 65:720–729.PubMedCrossRefGoogle Scholar
  48. Eiris-Punal J, Del Rio-Garma M, Del Rio-Garma MC, Lojo-Rocamonde S, Novo-Rodriguez I and Castro-Gago M (1999) Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia 40:1761–1766.PubMedCrossRefGoogle Scholar
  49. Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez R, Vlasuk GP and Harnish DC (2009) A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol 296:G543–G552.Google Scholar
  50. Fang HL, Strom SC, Ellis E, Duanmu Z, Fu J, Duniec-Dmuchowski Z, Falany CN, Falany JL, Kocarek TA and Runge-Morris M (2007) Positive and Negative Regulation of Human Hepatic Hydroxysteroid Sulfotransferase (SULT2A1) Gene Transcription by Rifampicin: Roles of Hepatocyte Nuclear Factor 4? and Pregnane X Receptor. J Pharmacol Exp Ther 323:586–590.PubMedCrossRefGoogle Scholar
  51. Ferguson SS, LeCluyse EL, Negishi M and Goldstein JA (2002) Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site. Mol Pharmacol 62:737–746.PubMedCrossRefGoogle Scholar
  52. Figge A, Lammert F, Paigen B, Henkel A, Matern S, Korstanje R, Shneider BL, Chen F, Stoltenberg E, Spatz K, Hoda F, Cohen DE and Green RM (2004) Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis. J Biol Chem 279:2790–2799.PubMedCrossRefGoogle Scholar
  53. Finch CK, Chrisman CR, Baciewicz AM and Self TH (2002) Rifampin and rifabutin drug interactions: an update. Arch Intern Med 162:985–992.PubMedCrossRefGoogle Scholar
  54. Finkelstein D, Lamba V, Assem M, Rengelshausen J, Yasuda K, Strom S and Schuetz E (2006) ADME transcriptome in Hispanic versus White donor livers: evidence of a globally enhanced NR1I3 (CAR, constitutive androstane receptor) gene signature in Hispanics. Xenobiotica 36:989–1012.PubMedCrossRefGoogle Scholar
  55. Finn RD, Henderson CJ, Scott CL and Wolf CR (2009) Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway. Biochem J 417:43–54.PubMedCrossRefGoogle Scholar
  56. Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, Gu XH, Foster P, Li J, Pircher P, Petrowski M, Schulman I, Westin S, Wrobel J, Yan G, Bischoff E, Daige C and Mohan R (2009) Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem Jan 21. [Epub ahead of print].Google Scholar
  57. Forman BM, Tzameli I, Choi HS, Chen J, Simha D, Seol W, Evans RM and Moore DD (1998) Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 395:612–615.PubMedCrossRefGoogle Scholar
  58. Frankenberg T, Miloh T, Chen FY, Ananthanarayanan M, Sun AQ, Balasubramaniyan N, Arias I, Setchell KD, Suchy FJ and Shneider BL (2008) The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology 48:1896–1905.PubMedCrossRefGoogle Scholar
  59. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W and Schrenk D (2000) The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157:1575–1580.PubMedGoogle Scholar
  60. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW and Egorin MJ (2004) Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76:323–329.PubMedCrossRefGoogle Scholar
  61. Gallicano KD, Sahai J, Shukla VK, Seguin I, Pakuts A, Kwok D, Foster BC and Cameron DW (1999) Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol 48:168–179.PubMedCrossRefGoogle Scholar
  62. Gardner-Stephen D, Heydel JM, Goyal A, Lu Y, Xie W, Lindblom T, Mackenzie P and Radominska-Pandya A (2004) Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab Dispos 32:340–347.PubMedCrossRefGoogle Scholar
  63. Geick A, Eichelbaum M and Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581–14587.PubMedCrossRefGoogle Scholar
  64. Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ and Maurel P (2002) Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 277:209–217.PubMedCrossRefGoogle Scholar
  65. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere N and Maurel P (2001) Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29:242–251.PubMedGoogle Scholar
  66. Gineste R, Sirvent A, Paumelle R, Helleboid S, Aquilina A, Darteil R, Hum DW, Fruchart JC and Staels B (2008) Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol Endocrinol 22:2433–2447.PubMedCrossRefGoogle Scholar
  67. Gnerre C, Blattler S, Kaufmann MR, Looser R and Meyer UA (2004) Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14:635–645.PubMedCrossRefGoogle Scholar
  68. Goodwin B, Hodgson E and Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329–1339.PubMedGoogle Scholar
  69. Goodwin B, Moore LB, Stoltz CM, McKee DD and Kliewer SA (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60:427–431.PubMedGoogle Scholar
  70. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M and Hall SD (2004) The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 75:89–100.PubMedCrossRefGoogle Scholar
  71. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147–153.PubMedCrossRefGoogle Scholar
  72. Hariparsad N, Carr BA, Evers R and Chu X (2008) Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 36:1046–1055.PubMedCrossRefGoogle Scholar
  73. Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA and Evans MJ (2009) Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res Jan 27. [Epub ahead of print].Google Scholar
  74. Hayashi A, Suzuki H, Itoh K, Yamamoto M and Sugiyama Y (2003) Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem Biophys Res Commun 310:824–829.PubMedCrossRefGoogle Scholar
  75. Healan-Greenberg C, Waring JF, Kempf DJ, Blomme EA, Tirona RG and Kim RB (2008) A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos 36:500–507.PubMedCrossRefGoogle Scholar
  76. Hendrix CW, Wakeford J, Wire MB, Lou Y, Bigelow GE, Martinez E, Christopher J, Fuchs EJ and Snidow JW (2004) Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacotherapy 24:1110–1121.PubMedCrossRefGoogle Scholar
  77. Hoekstra M, Lammers B, Out R, Li Z, Van Eck M and Van Berkel TJ (2009) Activation of the nuclear receptor PXR decreases plasma LDL-cholesterol levels and induces hepatic steatosis in LDL receptor knockout mice. Mol Pharm 6:182–189.PubMedCrossRefGoogle Scholar
  78. Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA and Hankinson O (1991) Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 252:954–958.PubMedCrossRefGoogle Scholar
  79. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M and Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478.PubMedCrossRefGoogle Scholar
  80. Honkakoski P, Zelko I, Sueyoshi T and Negishi M (1998) The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 18:5652–5658.PubMedGoogle Scholar
  81. Hosseinpour F, Timsit Y, Koike C, Matsui K, Yamamoto Y, Moore R and Negishi M (2007) Overexpression of the Rho-guanine nucleotide exchange factor ECT2 inhibits nuclear translocation of nuclear receptor CAR in the mouse liver. FEBS Lett 581:4937–4942.PubMedCrossRefGoogle Scholar
  82. Huang H, Wang H, Sinz M, Zoeckler M, Staudinger J, Redinbo MR, Teotico DG, Locker J, Kalpana GV and Mani S (2007) Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26:258–268.PubMedCrossRefGoogle Scholar
  83. Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R and Moore DD (2003) Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci USA 100:4156–4161.PubMedCrossRefGoogle Scholar
  84. Huang W, Zhang J and Moore DD (2004) A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J Clin Invest 113:137–143.PubMedGoogle Scholar
  85. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L and Burk O (2001) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454–1459.PubMedGoogle Scholar
  86. Huwyler J, Wright MB, Gutmann H and Drewe J (2006) Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr Drug Metab 7:119–126.PubMedCrossRefGoogle Scholar
  87. Inoue K and Negishi M (2008) Nuclear receptor CAR requires early growth response 1 to activate the human cytochrome P450 2B6 gene. J Biol Chem 283:10425–10432.PubMedCrossRefGoogle Scholar
  88. Itoh M, Nakajima M, Higashi E, Yoshida R, Nagata K, Yamazoe Y and Yokoi T (2006) Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. J Pharmacol Exp Ther 319:693–702.PubMedCrossRefGoogle Scholar
  89. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M and Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther 66:338–345.PubMedCrossRefGoogle Scholar
  90. Jung D, Elferink MG, Stellaard F and Groothuis GM (2007) Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int 27:137–144.PubMedCrossRefGoogle Scholar
  91. Jung D, Mangelsdorf DJ and Meyer UA (2006) Pregnane X receptor is a target of farnesoid X receptor. J Biol Chem 281:19081–19091.PubMedCrossRefGoogle Scholar
  92. Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, Fried M, Meier PJ and Kullak-Ublick GA (2002) Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 122:1954–1966.PubMedCrossRefGoogle Scholar
  93. Justesen US, Klitgaard NA, Brosen K and Pedersen C (2003) Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 55:100–106.PubMedCrossRefGoogle Scholar
  94. Kaeding J, Bouchaert E, Belanger J, Caron P, Chouinard S, Verreault M, Larouche O, Pelletier G, Staels B, Belanger A and Barbier O (2008) Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells. Biochem J 410:245–253.PubMedCrossRefGoogle Scholar
  95. Kanebratt KP and Andersson TB (2008) HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36:137–145.PubMedCrossRefGoogle Scholar
  96. Kang MI, Kobayashi A, Wakabayashi N, Kim SG and Yamamoto M (2004) Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. Proc Natl Acad Sci USA 101:2046–2051.PubMedCrossRefGoogle Scholar
  97. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM and Edwards PA (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277:2908–2915.PubMedCrossRefGoogle Scholar
  98. Kawaguchi A, Ohmori M, Tsuruoka S, Nishiki K, Harada K, Miyamori I, Yano R, Nakamura T, Masada M and Fujimura A (2004) Drug interaction between St John’s Wort and quazepam. Br J Clin Pharmacol 58:403–410.PubMedCrossRefGoogle Scholar
  99. Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K and Negishi M (1999) Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol 19:6318–6322.PubMedGoogle Scholar
  100. Kennedy J, Wang CC and Wu CH (2008) Patient disclosure about herb and supplement use among adults in the US. Evid Based Complement Alternat Med 5:451–456.PubMedCrossRefGoogle Scholar
  101. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG and Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199.PubMedCrossRefGoogle Scholar
  102. Kim DL, Song KH, Lee JH, Lee KY and Kim SK (2007) Rifampin-induced hypothyroidism without underlying thyroid disease. Thyroid 17:793–795.PubMedCrossRefGoogle Scholar
  103. King JR and Acosta EP (2006) Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet 45:665–682.PubMedCrossRefGoogle Scholar
  104. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, Perlmann T and Lehmann JM (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73–82.PubMedCrossRefGoogle Scholar
  105. Kobayashi K, Yamanaka Y, Iwazaki N, Nakajo I, Hosokawa M, Negishi M and Chiba K (2005) Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos 33:924–929.PubMedCrossRefGoogle Scholar
  106. Kocarek TA, Schuetz EG, Strom SC, Fisher RA and Guzelian PS (1995) Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab Dispos 23:415–421.PubMedGoogle Scholar
  107. Kodama S, Tanaka K, Konishi H, Momota K, Nakasako H, Nakayama S, Yagi J and Koderazawa K (1989) Supplementary thyroxine therapy in patients with hypothyroidism induced by long-term anticonvulsant therapy. Acta Paediatr Jpn 31:555–562.PubMedGoogle Scholar
  108. Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T and Boger RH (2000) Drug–drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 38:504–513.PubMedGoogle Scholar
  109. Kong B, Luyendyk JP, Tawfik O and Guo GL (2009) Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 328:116–122.PubMedCrossRefGoogle Scholar
  110. Kovacs P, Kress R, Rocha J, Kurtz U, Miquel JF, Nervi F, Mendez-Sanchez N, Uribe M, Bock HH, Schirin-Sokhan R, Stumvoll M, Mossner J, Lammert F and Wittenburg H (2008) Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J Hepatol 48:116–124.PubMedCrossRefGoogle Scholar
  111. Koyano S, Kurose K, Ozawa S, Saeki M, Nakajima Y, Hasegawa R, Komamura K, Ueno K, Kamakura S, Nakajima T, Saito H, Kimura H, Goto Y, Saitoh O, Katoh M, Ohnuma T, Kawai M, Sugai K, Ohtsuki T, Suzuki C, Minami N, Saito Y and Sawada J (2002) Eleven novel single nucleotide polymorphisms in the NR1I2 (PXR) gene, four of which induce non-synonymous amino acid alterations. Drug Metab Pharmacokinet 17:561–565.PubMedCrossRefGoogle Scholar
  112. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M and Kensler TW (2003) Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 278:8135–8145.PubMedCrossRefGoogle Scholar
  113. Lamba J, Lamba V, Strom S, Venkataramanan R and Schuetz E (2008) Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 36:169–181.PubMedCrossRefGoogle Scholar
  114. Lamba JK, Lin YS, Schuetz EG and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271–1294.PubMedCrossRefGoogle Scholar
  115. Lamba V, Yasuda K, Lamba JK, Assem M, Davila J, Strom S and Schuetz EG (2004) PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 199:251–265.PubMedCrossRefGoogle Scholar
  116. Lambert CB, Spire C, Claude N and Guillouzo A (2009a) Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol 234:345–360.PubMedCrossRefGoogle Scholar
  117. Lambert CB, Spire C, Renaud MP, Claude N and Guillouzo A (2009b) Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro 23:466–475.PubMedCrossRefGoogle Scholar
  118. Landrier JF, Eloranta JJ, Vavricka SR and Kullak-Ublick GA (2006) The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am J Physiol Gastrointest Liver Physiol 290:G476–G485.PubMedCrossRefGoogle Scholar
  119. Langmade SJ, Gale SE, Frolov A, Mohri I, Suzuki K, Mellon SH, Walkley SU, Covey DF, Schaffer JE and Ory DS (2006) Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc Natl Acad Sci USA 103:13807–13812.PubMedCrossRefGoogle Scholar
  120. Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W and Schmitz G (2004) Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 127:26–40.PubMedCrossRefGoogle Scholar
  121. Lazarou J, Pomeranz BH and Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc 279:1200–1205.CrossRefGoogle Scholar
  122. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT and Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016–1023.PubMedCrossRefGoogle Scholar
  123. Li L, Chen T, Stanton JD, Sueyoshi T, Negishi M and Wang H (2008) The peripheral benzodiazepine receptor ligand 1-(2-chlorophenyl-methylpropyl)-3-isoquinoline-carboxamide is a novel antagonist of human constitutive androstane receptor. Mol Pharmacol 74:443–453.PubMedCrossRefGoogle Scholar
  124. Li Y, Ross-Viola JS, Shay NF, Moore DD and Ricketts ML (2009b) Human CYP3A4 and murine Cyp3A11 are regulated by equol and genistein via the pregnane X receptor in a species-specific manner. J Nutr 139::898–904.CrossRefGoogle Scholar
  125. Li L, Stanton JD, Tolson AH, Luo Y and Wang H (2009a) Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 26:872–882.PubMedCrossRefGoogle Scholar
  126. Li YT, Swales KE, Thomas GJ, Warner TD and Bishop-Bailey D (2007) Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 27:2606–2611.PubMedCrossRefGoogle Scholar
  127. Lim YP, Liu CH, Shyu LJ and Huang JD (2005) Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects. Pharmacogenet Genomics 15:337–341.PubMedCrossRefGoogle Scholar
  128. Lloyd P, Flesch G and Dieterle W (1994) Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 35 Suppl 3:S10–S13.PubMedCrossRefGoogle Scholar
  129. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, LeCluyse E and Gan LS (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795–804.PubMedCrossRefGoogle Scholar
  130. Ma X, Cheung C, Krausz KW, Shah YM, Wang T, Idle JR and Gonzalez FJ (2008) A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab Dispos 36:2506–2512.PubMedCrossRefGoogle Scholar
  131. Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR and Gonzalez FJ (2007) Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 322:391–398.PubMedCrossRefGoogle Scholar
  132. Maglich JM, Lobe DC and Moore JT (2009) The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. J Lipid Res 50:439–445.PubMedCrossRefGoogle Scholar
  133. Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM and Moore JT (2003) Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem 278:17277–17283.PubMedCrossRefGoogle Scholar
  134. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT and Kliewer SA (2002) Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62:638–646.PubMedCrossRefGoogle Scholar
  135. Mai I, Stormer E, Bauer S, Kruger H, Budde K and Roots I (2003) Impact of St John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 18:819–822.PubMedCrossRefGoogle Scholar
  136. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR and Mangelsdorf DJ (2002) Vitamin D receptor as an intestinal bile acid sensor. Science 296:1313–1316.PubMedCrossRefGoogle Scholar
  137. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ and Shan B (1999) Identification of a nuclear receptor for bile acids. Science 284:1362–1365.PubMedCrossRefGoogle Scholar
  138. Mangelsdorf DJ and Evans RM (1995) The RXR heterodimers and orphan receptors. Cell 83:841–850.PubMedCrossRefGoogle Scholar
  139. Mani S, Huang H, Sundarababu S, Liu W, Kalpana G, Smith AB and Horwitz SB (2005) Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Clin Cancer Res 11:6359–6369.PubMedCrossRefGoogle Scholar
  140. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS and Chavin KD (2003) Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. J Am Med Assoc 290:1500–1504.CrossRefGoogle Scholar
  141. Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG and Kim RB (2007) A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol 21:1769–1780.PubMedCrossRefGoogle Scholar
  142. Masson D, Lagrost L, Athias A, Gambert P, Brimer-Cline C, Lan L, Schuetz JD, Schuetz EG and Assem M (2005) Expression of the pregnane X receptor in mice antagonizes the cholic acid-mediated changes in plasma lipoprotein profile. Arterioscler Thromb Vasc Biol 25:2164–2169.PubMedCrossRefGoogle Scholar
  143. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ and Sparreboom A (2002) Effects of St. John’s wort on irinotecan metabolism. J Natl Cancer Inst 94:1247–1249.PubMedGoogle Scholar
  144. McCance-Katz EF, Rainey PM, Friedland G and Jatlow P (2003) The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 37:476–482.PubMedCrossRefGoogle Scholar
  145. McCarthy TC, Li X and Sinal CJ (2005) Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J Biol Chem 280:23232–23242.PubMedCrossRefGoogle Scholar
  146. McGinnity DF, Zhang G, Kenny J, Hamilton G, Otmani S, Stams K, Haney S, Brassil P, Stresser DM and Riley RJ (2009) Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, PXR reporter gene, Fa2N-4 and HepaRG cells. Drug Metab Dispos Mar 23. [Epub ahead of print].Google Scholar
  147. Mencarelli A, Renga B, Distrutti E and Fiorucci S (2009) Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol 296:H272–H281.PubMedCrossRefGoogle Scholar
  148. Merrell MD, Jackson JP, Augustine LM, Fisher CD, Slitt AL, Maher JM, Huang W, Moore DD, Zhang Y, Klaassen CD and Cherrington NJ (2008) The Nrf2 activator oltipraz also activates the constitutive androstane receptor. Drug Metab Dispos 36:1716–1721.PubMedCrossRefGoogle Scholar
  149. Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH and Kim RB (2008) Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res 68:9338–9347.PubMedCrossRefGoogle Scholar
  150. Miki Y, Suzuki T, Kitada K, Yabuki N, Shibuya R, Moriya T, Ishida T, Ohuchi N, Blumberg B and Sasano H (2006) Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res 66:535–542.PubMedCrossRefGoogle Scholar
  151. Mills JB, Rose KA, Sadagopan N, Sahi J and de Morais SM (2004) Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 309:303–309.PubMedCrossRefGoogle Scholar
  152. Miyata M, Matsuda Y, Tsuchiya H, Kitada H, Akase T, Shimada M, Nagata K, Gonzalez FJ and Yamazoe Y (2006) Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase. Drug Metab Pharmacokinet 21:315–323.PubMedCrossRefGoogle Scholar
  153. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL and Kliewer SA (2000a) St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500–7502.PubMedCrossRefGoogle Scholar
  154. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, Collins JL and Kliewer SA (2000b) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122–15127.PubMedCrossRefGoogle Scholar
  155. Moreno-Torres A, Domingo P, Pujol J, Blanco-Vaca F, Arroyo JA and Sambeat MA (2007) Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy. Antivir Ther 12:195–203.PubMedGoogle Scholar
  156. Moschetta A, Bookout AL and Mangelsdorf DJ (2004) Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med 10:1352–1358.PubMedCrossRefGoogle Scholar
  157. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH and Watkins PB (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72:1–9.PubMedCrossRefGoogle Scholar
  158. Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M and Dusek A (1999) Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis 179:1116–1123.PubMedCrossRefGoogle Scholar
  159. Narang VS, Fraga C, Kumar N, Shen J, Throm S, Stewart CF and Waters CM (2008) Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am J Physiol Cell Physiol 295:C440–C450.PubMedCrossRefGoogle Scholar
  160. Nebel A, Schneider BJ, Baker RK and Kroll DJ (1999) Potential metabolic interaction between St. John’s wort and theophylline. Ann Pharmacother 33:502.PubMedCrossRefGoogle Scholar
  161. Nguyen T, Huang HC and Pickett CB (2000) Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK. J Biol Chem 275:15466–15473.PubMedCrossRefGoogle Scholar
  162. Ohtsuka H, Abe T, Onogawa T, Kondo N, Sato T, Oshio H, Mizutamari H, Mikkaichi T, Oikawa M, Rikiyama T, Katayose Y and Unno M (2006) Farnesoid X receptor, hepatocyte nuclear factors 1alpha and 3beta are essential for transcriptional activation of the liver-specific organic anion transporter-2 gene. J Gastroenterol 41:369–377.PubMedCrossRefGoogle Scholar
  163. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD and Lehmann JM (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284:1365–1368.PubMedCrossRefGoogle Scholar
  164. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P and Vilarem MJ (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268:6346–6358.PubMedCrossRefGoogle Scholar
  165. Pascussi JM, Jounaidi Y, Drocourt L, Domergue J, Balabaud C, Maurel P and Vilarem MJ (1999) Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem Biophys Res Commun 260:377–381.PubMedCrossRefGoogle Scholar
  166. Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, Pineau T, Saric J, Navarro F, Maurel P and Vilarem MJ (2005) Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 115:177–186.PubMedGoogle Scholar
  167. Peng CC, Glassman PA, Trilli LE, Hayes-Hunter J and Good CB (2004) Incidence and severity of potential drug-dietary supplement interactions in primary care patients: an exploratory study of 2 outpatient practices. Arch Intern Med 164:630–636.PubMedCrossRefGoogle Scholar
  168. Pentikis HS, Connolly M, Trapnell CB, Forbes WP and Bettenhausen DK (2007) The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 27:1361–1369.PubMedCrossRefGoogle Scholar
  169. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ and von Moltke LL (2005) Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 33:764–770.PubMedCrossRefGoogle Scholar
  170. Pickett CBPD, Nguyen T and Nioi P (2009) The Nrf2-ARE signaling pathway and its activation by oxidative stress. J Biol Chem Jan 30. [Epub ahead of print].Google Scholar
  171. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM and Falloon J (2000) Indinavir concentrations and St John’s wort. Lancet 355:547–548.PubMedCrossRefGoogle Scholar
  172. Piscitelli SC, Burstein AH, Welden N, Gallicano KD and Falloon J (2002) The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 34:234–238.PubMedCrossRefGoogle Scholar
  173. Plass JR, Mol O, Heegsma J, Geuken M, Faber KN, Jansen PL and Muller M (2002) Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology 35:589–596.PubMedCrossRefGoogle Scholar
  174. Poland A, Glover E and Kende AS (1976) Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J Biol Chem 251:4936–4946.PubMedGoogle Scholar
  175. Pondugula SR, Brimer-Cline C, Wu J, Schuetz EG, Tyagi RK and Chen T (2009) A phosphomimetic mutation at threonine-57 abolishes transactivation activity and alters nuclear localization pattern of human pregnane x receptor. Drug Metab Dispos 37:719–730.PubMedCrossRefGoogle Scholar
  176. Portoles A, Terleira A, Calvo A, Martinez I and Resplandy G (2006) Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol 46:1188–1194.PubMedCrossRefGoogle Scholar
  177. Qatanani M, Zhang J and Moore DD (2005) Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism. Endocrinology 146:995–1002.PubMedCrossRefGoogle Scholar
  178. Qureshi GD, Reinders TP, Somori GJ and Evans HJ (1984) Warfarin resistance with nafcillin therapy. Ann Intern Med 100:527–529.PubMedGoogle Scholar
  179. Raucy J, Warfe L, Yueh MF and Allen SW (2002) A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. J Pharmacol Exp Ther 303:412–423.PubMedCrossRefGoogle Scholar
  180. Remmer H, Schoene B and Fleischmann RA (1973) Induction of the unspecific microsomal hydroxylase in the human liver. Drug Metab Dispos 1:224–230.PubMedGoogle Scholar
  181. Ricketts ML, Boekschoten MV, Kreeft AJ, Hooiveld GJ, Moen CJ, Muller M, Frants RR, Kasanmoentalib S, Post SM, Princen HM, Porter JG, Katan MB, Hofker MH and Moore DD (2007) The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors. Mol Endocrinol 21:1603–1616.PubMedCrossRefGoogle Scholar
  182. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ and Hui DY (2001) HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 276:37514–37519.PubMedCrossRefGoogle Scholar
  183. Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS and de Morais SM (2006) Use of immortalized human hepatocytes to predict the magnitude of clinical drug–drug interactions caused by CYP3A4 induction. Drug Metab Dispos 34:1742–1748.PubMedCrossRefGoogle Scholar
  184. Rizzo G, Renga B, Antonelli E, Passeri D, Pellicciari R and Fiorucci S (2005) The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol 68:551–558.PubMedCrossRefGoogle Scholar
  185. Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM and Penzak SR (2008) Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 24:591–599.PubMedCrossRefGoogle Scholar
  186. Ruschitzka F, Meier PJ, Turina M, Luscher TF and Noll G (2000) Acute heart transplant rejection due to Saint John’s wort. Lancet 355:548–549.PubMedCrossRefGoogle Scholar
  187. Saeki M, Kurose K, Tohkin M and Hasegawa R (2008) Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem Pharmacol 76:531–542.PubMedCrossRefGoogle Scholar
  188. Sandanaraj E, Lal S, Selvarajan V, Ooi LL, Wong ZW, Wong NS, Ang PC, Lee EJ and Chowbay B (2008) PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res 14:7116–7126.PubMedCrossRefGoogle Scholar
  189. Scheer N, Ross J, Rode A, Zevnik B, Niehaves S, Faust N and Wolf CR (2008) A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest 118:3228–3239.PubMedCrossRefGoogle Scholar
  190. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS and Watkins PB (1997) Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1?,25-dihydroxyvitamin D3. Mol Pharmacol 51:741–754.PubMedGoogle Scholar
  191. Schoene B, Fleischmann RA, Remmer H and von Oldershausen HF (1972) Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur J Clin Pharmacol 4:65–73.PubMedCrossRefGoogle Scholar
  192. Schuetz E, Lan L, Yasuda K, Kim R, Kocarek TA, Schuetz J and Strom S (2002) development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. Mol Pharmacol 62:439–445.PubMedCrossRefGoogle Scholar
  193. Schuetz EG, Schinkel AH, Relling MV and Schuetz JD (1996) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001–4005.PubMedCrossRefGoogle Scholar
  194. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ and Schuetz JD (2001) Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 276:39411–39418.PubMedCrossRefGoogle Scholar
  195. Schwarz UI, Buschel B and Kirch W (2003) Unwanted pregnancy on self-medication with St John’s wort despite hormonal contraception. Br J Clin Pharmacol 55:112–113.PubMedCrossRefGoogle Scholar
  196. Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB and Kirch W (2007) Induction of intestinal P-glycoprotein by St John’s wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 81:669–678.PubMedCrossRefGoogle Scholar
  197. Shah YM, Ma X, Morimura K, Kim I and Gonzalez FJ (2007) Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol 292:G1114–G1122.Google Scholar
  198. Shah SC, Sharma RK, Hemangini and Chitle AR (1981) Rifampicin induced osteomalacia. Tubercle 62:207–209.PubMedCrossRefGoogle Scholar
  199. Shulman AI, Larson C, Mangelsdorf DJ and Ranganathan R (2004) Structural determinants of allosteric ligand activation in RXR heterodimers. Cell 116:417–429.PubMedCrossRefGoogle Scholar
  200. Siccardi M, D‘Avolio A, Baietto L, Gibbons S, Sciandra M, Colucci D, Bonora S, Khoo S, Back DJ, Di Perri G and Owen A (2008) Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396–->T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 47:1222–1225.PubMedCrossRefGoogle Scholar
  201. Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS and Evans RM (2002) Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci USA 99:13801–13806.PubMedCrossRefGoogle Scholar
  202. Sporstol M, Tapia G, Malerod L, Mousavi SA and Berg T (2005) Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I. Biochem Biophys Res Commun 331:1533–1541.PubMedCrossRefGoogle Scholar
  203. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P and Negishi M (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 274:6043–6046.PubMedCrossRefGoogle Scholar
  204. Sueyoshi T, Moore R, Sugatani J, Matsumura Y and Negishi M (2008) PPP1R16A, the membrane subunit of protein phosphatase 1beta, signals nuclear translocation of the nuclear receptor constitutive active/androstane receptor. Mol Pharmacol 73:1113–1121.PubMedCrossRefGoogle Scholar
  205. Sugatani J, Kojima H, Ueda A, Kakizaki S, Yoshinari K, Gong QH, Owens IS, Negishi M and Sueyoshi T (2001) The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 33:1232–1238.PubMedCrossRefGoogle Scholar
  206. Sugatani J, Yamakawa K, Tonda E, Nishitani S, Yoshinari K, Degawa M, Abe I, Noguchi H and Miwa M (2004) The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem Pharmacol 67:989–1000.PubMedCrossRefGoogle Scholar
  207. Suino K, Peng L, Reynolds R, Li Y, Cha JY, Repa JJ, Kliewer SA and Xu HE (2004) The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. Mol Cell 16:893–905.PubMedGoogle Scholar
  208. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD and Thomas DL (2005) Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. Aids 19:585–592.PubMedCrossRefGoogle Scholar
  209. Synold TW, Dussault I and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584–590.PubMedCrossRefGoogle Scholar
  210. Takagi S, Nakajima M, Mohri T and Yokoi T (2008) Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283:9674–9680.PubMedCrossRefGoogle Scholar
  211. Teotico DG, Bischof JJ, Peng L, Kliewer SA and Redinbo MR (2008) Structural basis of human pregnane X receptor activation by the hops constituent colupulone. Mol Pharmacol 74:1512–1520.PubMedCrossRefGoogle Scholar
  212. Terzolo M, Borretta G, Ali A, Cesario F, Magro G, Boccuzzi A, Reimondo G and Angeli A (1995) Misdiagnosis of Cushing’s syndrome in a patient receiving rifampicin therapy for tuberculosis. Horm Metab Res 27:148–150.PubMedCrossRefGoogle Scholar
  213. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y, Ishizuka H, Kharasch E, Schuetz J and Schuetz E (2001) Transcriptional control of intestinal cytochrome P-4503A by 1α,25-dihydroxyvitamin D3. Mol Pharmacol 60:1399–1406.PubMedGoogle Scholar
  214. Tirona RG and Kim RB (2009) Nuclear receptors and drug–drug interactions with prescription and herbal medicines, in Nuclear Receptors in Drug Metabolism (Xie W ed) pp. 211–239, Wiley, Hoboken, NJ.Google Scholar
  215. Tirona RG, Leake BF, Podust LM and Kim RB (2004) Identification of amino acids in rat pregnane X receptor that determine species-specific activation. Mol Pharmacol 65:36–44.PubMedCrossRefGoogle Scholar
  216. Tirona RG, Leake BF, Wolkoff AW and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223–228.PubMedCrossRefGoogle Scholar
  217. Tran JQ, Kovacs SJ, McIntosh TS, Davis HM and Martin DE (1999) Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol 39:487–494.PubMedGoogle Scholar
  218. Trapnell CB, Connolly M, Pentikis H, Forbes WP and Bettenhausen DK (2007) Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 41:222–228.PubMedCrossRefGoogle Scholar
  219. Trubetskoy O, Marks B, Zielinski T, Yueh MF and Raucy J (2005) A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. Aaps J 7:E6–E13.PubMedCrossRefGoogle Scholar
  220. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ and Moore DD (2002) A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296:1703–1706.PubMedCrossRefGoogle Scholar
  221. van Giersbergen PL, Gnerre C, Treiber A, Dingemanse J and Meyer UA (2002) Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. Eur J Pharmacol 450:115–121.PubMedCrossRefGoogle Scholar
  222. Van Mil SW, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, Shevchuk V, Moore GE, Lammert F, Glantz AG, Mattsson LA, Whittaker J, Parker MG, White R and Williamson C (2007) Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133:507–516.PubMedCrossRefGoogle Scholar
  223. Venugopal R and Jaiswal AK (1996) Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci U S A 93:14960–14965.PubMedCrossRefGoogle Scholar
  224. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, Yamamoto M, Kensler TW and Talalay P (2004) Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA 101:2040–2045.PubMedCrossRefGoogle Scholar
  225. Wang H, Chen J, Hollister K, Sowers LC and Forman BM (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3:543–553.PubMedCrossRefGoogle Scholar
  226. Wang YD, Chen WD, Wang M, Yu D, Forman BM and Huang W (2008b) Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48:1632–1643.PubMedCrossRefGoogle Scholar
  227. Wang H, Faucette SR, Moore R, Sueyoshi T, Negishi M and LeCluyse EL (2004a) Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem 279:29295–29301.PubMedCrossRefGoogle Scholar
  228. Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M and LeCluyse EL (2003) A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 278:14146–14152.PubMedCrossRefGoogle Scholar
  229. Wang H, Huang H, Li H, Teotico DG, Sinz M, Baker SD, Staudinger J, Kalpana G, Redinbo MR and Mani S (2007) Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res 13:2488–2495.PubMedCrossRefGoogle Scholar
  230. Wang H, Li H, Moore LB, Johnson MD, Maglich JM, Goodwin B, Ittoop OR, Wisely B, Creech K, Parks DJ, Collins JL, Willson TM, Kalpana GV, Venkatesh M, Xie W, Cho SY, Roboz J, Redinbo M, Moore JT and Mani S (2008a) The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol 22:838–857.PubMedCrossRefGoogle Scholar
  231. Wang XD, Li JL, Su QB, Guan S, Chen J, Du J, He YW, Zeng J, Zhang JX, Chen X, Huang M and Zhou SF (2009) Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John’s wort-induced activity of cytochrome P450 3A4 enzyme. Br J Clin Pharmacol 67:255–261.PubMedCrossRefGoogle Scholar
  232. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, Li T, Liu J, Yang TL, Wang D, Zhong XY and Zhou HH (2004b) St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 75:191–197.PubMedCrossRefGoogle Scholar
  233. Watkins RE, Davis-Searles PR, Lambert MH and Redinbo MR (2003a) Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol 331:815–828.PubMedCrossRefGoogle Scholar
  234. Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, Davis-Searles PR, Lambert MH, Kliewer SA and Redinbo MR (2003b) 2.1 A crystal structure of human PXR in complex with the St. John’s wort compound hyperforin. Biochemistry 42:1430–1438.PubMedCrossRefGoogle Scholar
  235. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA and Redinbo MR (2001) The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292:2329–2333.PubMedCrossRefGoogle Scholar
  236. Wong H, Lehman-McKeeman LD, Grubb MF, Grossman SJ, Bhaskaran VM, Solon EG, Shen HS, Gerson RJ, Car BD, Zhao B and Gemzik B (2005) Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats. Toxicol Sci 84:232–242.PubMedCrossRefGoogle Scholar
  237. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-Tetri BA, Brunt EM, Guzelian PS and Evans RM (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435–439.PubMedCrossRefGoogle Scholar
  238. Xie Y, Ke S, Ouyang N, He J, Xie W, Bedford MT and Tian Y (2009) Epigenetic regulation of transcriptional activity of pregnane X receptor by protein arginine methyltransferase 1. J Biol Chem 284:9199–9205.PubMedCrossRefGoogle Scholar
  239. Xu RX, Lambert MH, Wisely BB, Warren EN, Weinert EE, Waitt GM, Williams JD, Collins JL, Moore LB, Willson TM and Moore JT (2004) A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. Mol Cell 16:919–928.PubMedCrossRefGoogle Scholar
  240. Yamazaki Y, Kakizaki S, Horiguchi N, Sohara N, Sato K, Takagi H, Mori M and Negishi M (2007) The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. Gut 56:565–574.PubMedCrossRefGoogle Scholar
  241. Yang D, Wang X, Chen YT, Deng R and Yan B (2009) Pyrethroid insecticides: Isoform-dependent hydrolysis, induction of cytochrome P450 3A4 and evidence on the involvement of the pregnane X receptor. Toxicol Appl Pharmacol Feb 26. [Epub ahead of print].Google Scholar
  242. Yang J and Yan B (2007) Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol Sci 95:13–22.PubMedCrossRefGoogle Scholar
  243. Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, Schuetz E and Bachmann K (2008) A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos 36:1689–1697.PubMedCrossRefGoogle Scholar
  244. Yeung EY, Sueyoshi T, Negishi M and Chang TK (2008) Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos 36:2270–2276.PubMedCrossRefGoogle Scholar
  245. Yin OQ, Tomlinson B, Waye MM, Chow AH and Chow MS (2004) Pharmacogenetics and herb–drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 14:841–850.PubMedCrossRefGoogle Scholar
  246. Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M and Moss J (2004) Brief communication: American ginseng reduces warfarin’s effect in healthy patients: a randomized, controlled trial. Ann Intern Med 141:23–27.PubMedGoogle Scholar
  247. Yue QY, Bergquist C and Gerden B (2000) Safety of St John’s wort (Hypericum perforatum). Lancet 355:576–577.PubMedCrossRefGoogle Scholar
  248. Zastre JA, Chan GN, Ronaldson PT, Ramaswamy M, Couraud PO, Romero IA, Weksler B, Bendayan M and Bendayan R (2009) Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res 87:1023–1036.PubMedCrossRefGoogle Scholar
  249. Zhai Y, Pai HV, Zhou J, Amico JA, Vollmer RR and Xie W (2007) Activation of pregnane X receptor disrupts glucocorticoid and mineralocorticoid homeostasis. Mol Endocrinol 21:138–147.PubMedCrossRefGoogle Scholar
  250. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson JR, Jr., Schuetz EG and Boguski MS (2001) The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555–572.PubMedCrossRefGoogle Scholar
  251. Zhang S, Liu Q, Wang J and Harnish DC (2009) Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem Biophys Res Commun 379:476–479.PubMedCrossRefGoogle Scholar
  252. Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG and Thummel KE (2006a) Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 116:1703–1712.PubMedCrossRefGoogle Scholar
  253. Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, Lee JH, Khadem S, Ren S, Li S, Silverstein RL and Xie W (2008a) Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 134:556–567.PubMedCrossRefGoogle Scholar
  254. Zhou J, Liu M, Zhai Y and Xie W (2008b) The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol Endocrinol 22:868–880.PubMedCrossRefGoogle Scholar
  255. Zhou C, Poulton EJ, Grun F, Bammler TK, Blumberg B, Thummel KE and Eaton DL (2007) The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol 71:220–229.PubMedCrossRefGoogle Scholar
  256. Zhou C, Tabb MM, Nelson EL, Grun F, Verma S, Sadatrafiei A, Lin M, Mallick S, Forman BM, Thummel KE and Blumberg B (2006b) Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 116:2280–2289.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Clinical Pharmacology, Department of Medicine, Department of Physiology & PharmacologySchulich School of Medicine and Dentisity, University of Western Ontario, London Health Sciences Centre - University HospitalLondonCanada

Personalised recommendations